{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T06:38:53Z","timestamp":1789799933929,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,6,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>To evaluate cytological DNA methylation testing methods for risk stratification in women with non-16\/18 HPV, focusing on high-risk HPV (hrHPV) genotyping.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study compared the triage performance of liquid-based cytology (LBC) testing, hrHPV genotyping, and <jats:italic>PAX1<\/jats:italic>\/<jats:italic>JAM3<\/jats:italic> gene methylation (CISCER) testing. The absolute risks of cervical intraepithelial neoplasia grade 2 or worse (CIN2+), grade 3 or worse (CIN3+), and colposcopy referral rates were calculated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The CISCER test showed a CIN3+ risk of 39.1% for positive and 0.9% for negative results. In comparison, LBC\u2009\u2265\u2009ASCUS and HPV33\/35 genotyping had CIN3+ risks of 9.8% and 19.3%, respectively, for positive result. The colposcopy referral rates were 17.4% for CISCER+, 61.9% for LBC\u2009\u2265\u2009ASCUS, and 8.9% for HPV33\/35+ genotyping. The CIN3+ risks were 40.0% and 50.0% when CISCER+ was combined with LBC\u2009\u2265\u2009ASCUS and HPV33\/35+, respectively. The CIN3+ risks were 0.0% and 1.0% when CISCER- was combined with LBC with no intraepithelial lesions or malignancy (NILM) and non-HPV33\/35, respectively. Our analysis of CIN2+ patients yielded similar results.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>DNA methylation testing outperformed LBC in triaging women with non-16\/18 hrHPV infections, significantly reducing unnecessary colposcopy referrals, particularly when combined with HPV33\/35 genotyping.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41416-025-03005-5","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T02:31:41Z","timestamp":1744252301000},"page":"1064-1071","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The triage role of cytological DNA methylation in women with non-16\/18, specifically genotyping high-risk HPV infection"],"prefix":"10.1038","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8014-7915","authenticated-orcid":false,"given":"Haiqi","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8561-046X","authenticated-orcid":false,"given":"Xitong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0270-0540","authenticated-orcid":false,"given":"Linghua","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4971-7830","authenticated-orcid":false,"given":"Yan","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3996-3176","authenticated-orcid":false,"given":"Huanwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3994-6250","authenticated-orcid":false,"given":"Yuligh","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8723-3461","authenticated-orcid":false,"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"3005_CR1","doi-asserted-by":"publisher","unstructured":"Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 12\u20139 https:\/\/doi.org\/10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F"},{"key":"3005_CR2","doi-asserted-by":"publisher","first-page":"918190","DOI":"10.3389\/fimmu.2022.918190","volume":"13","author":"W Dai","year":"2022","unstructured":"Dai W, Gui L, Du H, Li S, Wu R. The association of cervicovaginal Langerhans cells with clearance of human papillomavirus. Front Immunol. 2022;13:918190.","journal-title":"Front Immunol"},{"key":"3005_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/LGT.0000000000000788","volume":"28","author":"RB Perkins","year":"2024","unstructured":"Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP risk-based management consensus guidelines: updates through 2023. J Low Genit Trac Dis. 2024;28:3\u20136.","journal-title":"J Low Genit Trac Dis"},{"key":"3005_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","volume":"24","author":"RB Perkins","year":"2020","unstructured":"Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Trac Dis. 2020;24:102\u201331.","journal-title":"J Low Genit Trac Dis"},{"key":"3005_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7316","volume":"13","author":"C Dun","year":"2024","unstructured":"Dun C, Yuan M, Zhao X, Hu S, Arbyn M, Zhao F. Clinical evaluation of primary human papillomavirus (HPV) testing with extended HPV genotyping triage for cervical cancer screening: a pooled analysis of individual patient data from nine population-based cervical cancer screening studies from China. Cancer Med. 2024;13:e7316.","journal-title":"Cancer Med"},{"key":"3005_CR6","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3390\/cancers16030672","volume":"16","author":"CA Gon\u00e7alves","year":"2024","unstructured":"Gon\u00e7alves CA, Pereira-da-Silva G, Silveira R, Mayer PCM, Zilly A, Lopes-J\u00fanior LC. Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (cin 2\/3) associated with human papillomavirus: a systematic review. Cancers. 2024;16:672.","journal-title":"Cancers"},{"key":"3005_CR7","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1309\/AJCPXANG59GPHJNU","volume":"131","author":"AA Renshaw","year":"2009","unstructured":"Renshaw AA, Desch\u00eanes M, Auger M. ASC\/SIL ratio for cytotechnologists: a surrogate marker of screening sensitivity. Am J Clin Pathol. 2009;131:776\u201381.","journal-title":"Am J Clin Pathol"},{"key":"3005_CR8","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1109\/JBHI.2017.2705583","volume":"21","author":"L Zhang","year":"2017","unstructured":"Zhang L, Le L, Nogues I, Summers RM, Liu S, Yao J. DeepPap: deep convolutional networks for cervical cell classification. IEEE J Biomed Health Inf. 2017;21:1633\u201343.","journal-title":"IEEE J Biomed Health Inf"},{"key":"3005_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(12)70568-5","volume":"14","author":"N Wentzensen","year":"2013","unstructured":"Wentzensen N. Triage of HPV-positive women in cervical cancer screening. Lancet Oncol. 2013;14:107\u20139.","journal-title":"Lancet Oncol"},{"key":"3005_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ygyno.2016.10.031","volume":"144","author":"TC Wright Jr.","year":"2017","unstructured":"Wright TC Jr., Behrens CM, Ranger-Moore J, Rehm S, Sharma A, Stoler MH, et al. Triaging HPV-positive women with p16\/Ki-67 dual-stained cytology: results from a sub-study nested into the ATHENA trial. Gynecol Oncol. 2017;144:51\u201356.","journal-title":"Gynecol Oncol"},{"key":"3005_CR11","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/ijc.26056","volume":"130","author":"DC Rijkaart","year":"2012","unstructured":"Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Hesselink AT, Rozendaal L, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer. 2012;130:602\u201310.","journal-title":"Int J Cancer"},{"key":"3005_CR12","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1002\/ijc.31976","volume":"144","author":"DA Cook","year":"2019","unstructured":"Cook DA, Krajden M, Brentnall AR, Gondara L, Chan T, Law JH, et al. 2019_Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial. Int J Cancer. 2019;144:2587\u201395. https:\/\/doi.org\/10.1002\/ijc.31976.","journal-title":"Int J Cancer"},{"key":"3005_CR13","doi-asserted-by":"publisher","unstructured":"Bierkens M, Hesselink AT, Meijer CJLM, Heideman DAM, Wisman GBA, van der Zee AGJ, et al. CADM1andMALpromoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int J Cancer. 2023; 1293\u20139. https:\/\/doi.org\/10.1002\/ijc.28138.","DOI":"10.1002\/ijc.28138"},{"key":"3005_CR14","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ygyno.2021.02.011","volume":"161","author":"CL Chang","year":"2021","unstructured":"Chang CL, Ho SC, Su YF, Juan YC, Huang CY, Chao AS, et al. DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: real-world evidence in Taiwan. Gynecol Oncol. 2021;161:429\u201335.","journal-title":"Gynecol Oncol"},{"key":"3005_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4877-5","volume":"18","author":"Q Bu","year":"2018","unstructured":"Bu Q, Wang S, Ma J, Zhou X, Hu G, Deng H, et al. The clinical significance of FAM19A4 methylation in high-risk HPV-positive cervical samples for the detection of cervical (pre)cancer in Chinese women. BMC Cancer. 2018;18:1182.","journal-title":"BMC Cancer"},{"key":"3005_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ygyno.2018.09.006","volume":"151","author":"A Leeman","year":"2018","unstructured":"Leeman A, Ebisch RMF, Kasius A, Bosgraaf RP, Jenkins D, van de Sandt MM, et al. Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16\/18 and FAM19A4\/miR124-2 methylation. Gynecol Oncol. 2018;151:311\u20138.","journal-title":"Gynecol Oncol"},{"key":"3005_CR17","doi-asserted-by":"publisher","first-page":"125.e121","DOI":"10.1016\/j.cmi.2020.03.018","volume":"27","author":"FJ Vink","year":"2021","unstructured":"Vink FJ, Lissenberg-Witte BI, Meijer C, Berkhof J, van Kemenade FJ, Siebers AG, et al. FAM19A4\/miR124-2 methylation analysis as a triage test for HPV-positive women: cross-sectional and longitudinal data from a Dutch screening cohort. Clin Microbiol Infect. 2021;27:125.e121\u2013125.e126.","journal-title":"Clin Microbiol Infect"},{"key":"3005_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0743-9","volume":"11","author":"R Hern\u00e1ndez-L\u00f3pez","year":"2019","unstructured":"Hern\u00e1ndez-L\u00f3pez R, Lorincz AT, Torres-Ibarra L, Reuter C, Scibior-Bentkowska D, Warman R, et al. Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16\/18 genotyping. Clin Epigenet. 2019;11:140.","journal-title":"Clin Epigenet"},{"key":"3005_CR19","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1002\/ijc.30008","volume":"138","author":"AT Lorincz","year":"2016","unstructured":"Lorincz AT, Brentnall AR, Scibior-Bentkowska D, Reuter C, Banwait R, Cadman L, et al. Validation of a DNA methylation HPV triage classifier in a screening sample. Int J Cancer. 2016;138:2745\u201351.","journal-title":"Int J Cancer"},{"key":"3005_CR20","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/bjc.2014.392","volume":"111","author":"A Boers","year":"2014","unstructured":"Boers A, Bosgraaf RP, van Leeuwen RW, Schuuring E, Heideman DA, Massuger LF, et al. DNA methylation analysis in self-sampled brush material as a triage test in hrHPV-positive women. Br J Cancer. 2014;111:1095\u2013101.","journal-title":"Br J Cancer"},{"key":"3005_CR21","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/ijc.31897","volume":"144","author":"RW van Leeuwen","year":"2019","unstructured":"van Leeuwen RW, O\u0161trbenk A, Poljak M, van der Zee AGJ, Schuuring E, Wisman GBA. DNA methylation markers as a triage test for identification of cervical lesions in a high-risk human papillomavirus-positive screening cohort. Int J Cancer. 2019;144:746\u201354.","journal-title":"Int J Cancer"},{"key":"3005_CR22","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/ijc.26056","volume":"130","author":"DC Rijkaart","year":"2012","unstructured":"Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VMH, Hesselink AT, Rozendaal L, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer. 2012;130:602\u201310.","journal-title":"Int J Cancer"},{"key":"3005_CR23","doi-asserted-by":"publisher","unstructured":"Dong B, Zou H, Mao X, Su Y, Gao H, Xie F et al. Effect of introducing human papillomavirus genotyping into real-world screening on cervical cancer screening in China: a retrospective population-based cohort study. Ther Adv Med Oncol. 2021, 175883592110109. https:\/\/doi.org\/10.1177\/17588359211010939.","DOI":"10.1177\/17588359211010939"},{"key":"3005_CR24","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ygyno.2019.05.012","volume":"154","author":"TC Wright","year":"2019","unstructured":"Wright TC, Stoler MH, Parvu V, Yanson K, Cooper C, Andrews J. Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, \u226521 years of age, with ASC-US or LSIL cytology. Gynecol Oncol 2019;154:360\u20137.","journal-title":"Gynecol Oncol"},{"key":"3005_CR25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ygyno.2015.06.040","volume":"138","author":"M Schiffman","year":"2015","unstructured":"Schiffman M, Vaughan LM, Raine-Bennett TR, Castle PE, Katki HA, Gage JC, et al. A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. Gynecol Oncol 2015;138:573\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2015.06.040","journal-title":"Gynecol Oncol"},{"key":"3005_CR26","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1002\/ijc.33035","volume":"147","author":"T Malag\u00f3n","year":"2020","unstructured":"Malag\u00f3n T, Volesky KD, Bouten S, Laprise C, El-Zein M, Franco EL. Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: systematic review and meta-analysis. Int J Cancer. 2020;147:2695\u2013707.","journal-title":"Int J Cancer"},{"key":"3005_CR27","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/ijc.33430","volume":"148","author":"N Li","year":"2021","unstructured":"Li N, Hu Y, Zhang X, Liu Y, He Y, van der Zee AGJ, et al. DNA methylation markers as triage test for the early identification of cervical lesions in a Chinese population. Int J Cancer. 2021;148:1768\u201377.","journal-title":"Int J Cancer"},{"key":"3005_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-024-01731-w","volume":"16","author":"X Chen","year":"2024","unstructured":"Chen X, Jin X, Kong L, Liou Y, Liu P, Dong Z, et al. Triage performance of PAX1m\/JAM3m in opportunistic cervical cancer screening of non\u201216\/18 human papillomavirus-positive women: a multicenter prospective study in China. Clin Epigenet. 2024;16:108.","journal-title":"Clin Epigenet"},{"key":"3005_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/cncy.21521","volume":"123","author":"R Nayar","year":"2015","unstructured":"Nayar R, Wilbur DC. The Pap test and Bethesda 2014. Cancer Cytopathol. 2015;123:271\u201381.","journal-title":"Cancer Cytopathol"},{"key":"3005_CR30","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.3802\/jgo.2016.27.e56","volume":"27","author":"YE Sung","year":"2016","unstructured":"Sung YE, Ki EY, Lee YS, Hur SY, Lee A, Park JS. Can human papillomavirus (HPV) genotyping classify non-16\/18 high-risk HPV infection by risk stratification? J Gynecol Oncol. 2016;27:e56.","journal-title":"J Gynecol Oncol"},{"key":"3005_CR31","doi-asserted-by":"crossref","unstructured":"Quek SC, Lim BK, Domingo E, Soon R, Park J-S, Vu TN et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical intraepithelial neoplasia across 5 countries in Asia. Int J Gynecol Cancer. 2013; 23, 148\u201356.","DOI":"10.1097\/IGC.0b013e31827670fd"},{"key":"3005_CR32","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41416-021-01614-4","volume":"126","author":"S Dick","year":"2022","unstructured":"Dick S, Vink FJ, Heideman DAM, Lissenberg-Witte BI, Meijer C, Berkhof J. Risk-stratification of HPV-positive women with low-grade cytology by FAM19A4\/miR124-2 methylation and HPV genotyping. Br J Cancer. 2022;126:259\u201364.","journal-title":"Br J Cancer"},{"key":"3005_CR33","doi-asserted-by":"publisher","unstructured":"Louvanto K, Aro K, Nedjai B, B\u00fctzow R, Jakobsson M, Kalliala I et al. Methylation in predicting progression of untreated high-grade cervical intraepithelial neoplasia. https:\/\/doi.org\/10.1093\/cid\/ciz677, 2582\u201390 (2020).","DOI":"10.1093\/cid\/ciz677,"},{"key":"3005_CR34","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/ijc.34041","volume":"151","author":"L Zhang","year":"2022","unstructured":"Zhang L, Zhao X, Hu S, Chen S, Zhao S, Dong L, et al. Triage performance and predictive value of the human gene methylation panel among women positive on self-collected HPV test: results from a prospective cohort study. Int J Cancer. 2022;151:878\u201387.","journal-title":"Int J Cancer"},{"key":"3005_CR35","doi-asserted-by":"publisher","first-page":"e029017","DOI":"10.1136\/bmjopen-2019-029017","volume":"9","author":"WW Kremer","year":"2019","unstructured":"Kremer WW, Berkhof J, Bleeker MC, Heideman DA, van Trommel NE, van Baal MW, et al. Role of FAM19A4\/miR124-2 methylation analysis in predicting regression or non-regression of CIN2\/3 lesions: a protocol of an observational longitudinal cohort study. BMJ Open. 2019;9:e029017.","journal-title":"BMJ Open"},{"key":"3005_CR36","first-page":"Cd008587","volume":"8","author":"G Koliopoulos","year":"2017","unstructured":"Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017;8:Cd008587.","journal-title":"Cochrane Database Syst Rev"},{"key":"3005_CR37","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","volume":"383","author":"G Ronco","year":"2014","unstructured":"Ronco G, Dillner J, Elfstr\u00f6m KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524\u201332.","journal-title":"Lancet"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03005-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03005-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03005-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T16:13:45Z","timestamp":1748448825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03005-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,6,18]]}},"alternative-id":["3005"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03005-5","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"19 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Institutional Review Board of Peking Union Medical College Hospital has approved this study (No. JS-2380 and K-S2021211 for METHY3 and METHY4 respectively). The registration numbers are NCT04646954 and NCT05290428 (clinicaltrials.gov, registered on November 26, 2020 and March 12, 2022), respectively. Informed consent was obtained from the subjects prior to participating in the study. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and registration"}},{"value":"Consent for publication has been obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}